• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

    4.860 +0.200 (+4.29%)
    Streaming Delayed Price Updated: 10:04 AM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 17,571
    Open 4.660
    Bid (Size) 4.750 (3)
    Ask (Size) 4.860 (2)
    Prev. Close 4.660
    Today's Range 4.600 - 4.860
    52wk Range 4.480 - 43.65
    Shares Outstanding 1,524,535
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire

    Performance

    YTD
    -73.4%
    -73.4%
    1 Month
    -87.5%
    -87.5%
    3 Month
    -81.3%
    -81.3%
    6 Month
    -80.9%
    -80.9%
    1 Year
    -73.4%
    -73.4%

    More News

    Read More
    Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – TVRD
    From The Rosen Law Firm, P.A.
    Via Business Wire
    Unusual volume stocks in Monday's session
    Via Chartmill
    In today's session, these stocks are experiencing unusual volume.
    Via Chartmill
    Unusual volume stocks in Wednesday's session
    Via Chartmill
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
    From Faruqi & Faruqi, LLP
    Via Business Wire
    Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks
    Via Benzinga
    Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Dow Surges 1%; Fastenal Shares Fall After Q3 Results
    Via Benzinga
    Topics Stocks
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?
    Via Stocktwits
    Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Tvardi Posts Q2 Net Income Turnaround
    Via The Motley Fool
    Topics Intellectual Property
    Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
    Via Benzinga
    This Modine Manufacturing Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Tvardi Therapeutics to Participate in Upcoming Investor Conferences
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
    From Tvardi Therapeutics, Inc.
    Via Business Wire
    Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
    From Tvardi Therapeutics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Tvardi Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Tvardi Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Tvardi Therapeutics, Inc. - Common Stock trade on?
    Tvardi Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Tvardi Therapeutics, Inc. - Common Stock?
    The ticker symbol for Tvardi Therapeutics, Inc. - Common Stock is TVRD on the Nasdaq Stock Market
    What is the current price of Tvardi Therapeutics, Inc. - Common Stock?
    The current price of Tvardi Therapeutics, Inc. - Common Stock is 4.860
    When was Tvardi Therapeutics, Inc. - Common Stock last traded?
    The last trade of Tvardi Therapeutics, Inc. - Common Stock was at 10/31/25 10:04 AM ET
    What is the market capitalization of Tvardi Therapeutics, Inc. - Common Stock?
    The market capitalization of Tvardi Therapeutics, Inc. - Common Stock is 7.41M
    How many shares of Tvardi Therapeutics, Inc. - Common Stock are outstanding?
    Tvardi Therapeutics, Inc. - Common Stock has 7M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.